TY - JOUR
T1 - The JAK-STAT pathway at 30
T2 - Much learned, much more to do
AU - Philips, Rachael L.
AU - Wang, Yuxin
AU - Cheon, Hyeon Joo
AU - Kanno, Yuka
AU - Gadina, Massimo
AU - Sartorelli, Vittorio
AU - Horvath, Curt M.
AU - Darnell, James E.
AU - Stark, George R.
AU - O'Shea, John J.
N1 - Funding Information:
IFNs were first described over 70 years ago, leading to an extraordinary body of literature. Unfortunately, space limitations preclude including many outstanding citations—our apologies to all whose work could not be cited. This work was supported by the Intramural Research Programs of NIAMS . R.L.P. was supported by a Postdoctoral Research Associate (PRAT) fellowship from the National Institute of General Medical Sciences (NIGMS), award number 1Fi2GM137942-01 . Additionally, Y.W. was supported by the National Heart Lung and Blood Institute (NHLBI), award number R56 HL160639 , and G.R.S. was supported by the National Institute of Allergy and Infectious Diseases (NIAID), award number R01 AI153085 , and the National Cancer Institute (NCI), award number P01CA062220 . H.C. was supported by National Cancer Institute (NCI), award numbers R21CA252387 and R03CA215941 .
Funding Information:
IFNs were first described over 70 years ago, leading to an extraordinary body of literature. Unfortunately, space limitations preclude including many outstanding citations—our apologies to all whose work could not be cited. This work was supported by the Intramural Research Programs of NIAMS. R.L.P. was supported by a Postdoctoral Research Associate (PRAT) fellowship from the National Institute of General Medical Sciences (NIGMS), award number 1Fi2GM137942-01. Additionally, Y.W. was supported by the National Heart Lung and Blood Institute (NHLBI), award number R56 HL160639, and G.R.S. was supported by the National Institute of Allergy and Infectious Diseases (NIAID), award number R01 AI153085, and the National Cancer Institute (NCI), award number P01CA062220. H.C. was supported by National Cancer Institute (NCI), award numbers R21CA252387 and R03CA215941. The NIH holds a US patent related to JAK inhibitors, and Dr. O'Shea receives royalty income.
Publisher Copyright:
© 2022
PY - 2022/10/13
Y1 - 2022/10/13
N2 - The discovery of the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway arose from investigations of how cells respond to interferons (IFNs), revealing a paradigm in cell signaling conserved from slime molds to mammals. These discoveries revealed mechanisms underlying rapid gene expression mediated by a wide variety of extracellular polypeptides including cytokines, interleukins, and related factors. This knowledge has provided numerous insights into human disease, from immune deficiencies to cancer, and was rapidly translated to new drugs for autoimmune, allergic, and infectious diseases, including COVID-19. Despite these advances, major challenges and opportunities remain.
AB - The discovery of the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway arose from investigations of how cells respond to interferons (IFNs), revealing a paradigm in cell signaling conserved from slime molds to mammals. These discoveries revealed mechanisms underlying rapid gene expression mediated by a wide variety of extracellular polypeptides including cytokines, interleukins, and related factors. This knowledge has provided numerous insights into human disease, from immune deficiencies to cancer, and was rapidly translated to new drugs for autoimmune, allergic, and infectious diseases, including COVID-19. Despite these advances, major challenges and opportunities remain.
UR - http://www.scopus.com/inward/record.url?scp=85139736584&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139736584&partnerID=8YFLogxK
U2 - 10.1016/j.cell.2022.09.023
DO - 10.1016/j.cell.2022.09.023
M3 - Review article
C2 - 36240739
AN - SCOPUS:85139736584
SN - 0092-8674
VL - 185
SP - 3857
EP - 3876
JO - Cell
JF - Cell
IS - 21
ER -
